Related Experiment Video
Updated: Mar 19, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Hilde Almåsbak1, Tanja Aarvak1, Mohan C Vemuri2
1Cellular Medicine, Bioproduction, Thermo Fisher Scientific, 0309 Oslo, Norway.
Abstract:
The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinical responses in trials with gene modified T cells expressing chimeric antigen receptors (CARs) in B-cell malignancies have generated great enthusiasm. This therapy might pave the way for a potential paradigm shift in the way we treat refractory or relapsed cancers. CARs are genetically engineered receptors that combine the specific binding domains from a tumor targeting antibody with T cell signaling domains to allow specifically targeted antibody redirected T cell activation. Despite current successes in hematological cancers, we are only in the beginning of exploring the powerful potential of CAR redirected T cells in the control and elimination of resistant, metastatic, or recurrent nonhematological cancers. This review discusses the application of the CAR T cell therapy, its challenges, and strategies for successful clinical and commercial translation.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for refractory cancers, offering a potential paradigm shift in treatment. While successful in blood cancers, its application in solid tumors is still emerging.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Novel targeted therapies are crucial for improving cancer survival rates.
- Immunotherapy presents a promising avenue for inducing sustained remissions in refractory cancers.
- Chimeric antigen receptor (CAR) T cell therapy has demonstrated significant clinical responses in B-cell malignancies.
Purpose of the Study:
- To review the application of CAR T cell therapy in cancer treatment.
- To discuss the challenges associated with CAR T cell therapy.
- To explore strategies for the clinical and commercial translation of CAR T cell therapy.
Main Methods:
- Review of existing literature on CAR T cell therapy.
- Analysis of clinical trial data for CAR T cell therapy in hematological and nonhematological cancers.
- Discussion of the mechanisms of CAR T cell activation.
Main Results:
- CAR T cell therapy has shown dramatic clinical responses in B-cell malignancies.
- CAR T cell therapy has the potential to induce sustained remissions.
- The potential of CAR T cell therapy in nonhematological cancers is largely unexplored.
Conclusions:
- CAR T cell therapy represents a potential paradigm shift for refractory or relapsed cancers.
- Further research and development are needed to overcome challenges in applying CAR T cell therapy to nonhematological cancers.
- Successful clinical and commercial translation requires strategic planning and execution.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

